Cellectis posted a net loss attributable to shareholders of USD 39.6 million, or USD 0.39 a share, for the half-year ended June 30.
Revenue and other income fell 52.2% to USD 14.45 million, reflecting lower activity under its AstraZeneca research collaboration plans.
Operating loss widened to USD 48.69 million as R&D costs rose to USD 52.17 million on higher staffing and clinical development spending.
Net financial result swung to a gain of USD 9.18 million, driven by fair-value gains on EIB warrants and lower FX losses.
Cash, cash equivalents and term deposits totaled USD 169 million at June 30; cash runway guided through Q4 2027, with BALLI-01 interim Phase 2 data due Q4 2026.
CLLS•
